
"Potential Link Between RSV Vaccines and Guillain-Barré Syndrome Risk: Data Analysis"
New data from the CDC and FDA suggests a small increased risk of developing Guillain-Barré syndrome (GBS) after receiving RSV vaccines, particularly the Pfizer vaccine, among individuals aged 60 and older. However, it is still too early to determine the true risk and quantify its size. Vaccine safety experts are conducting further analysis, and the CDC continues to support the use of RSV vaccines in this age group due to the burden of RSV disease. The CDC is also considering changing its recommendation for RSV vaccination, and both Pfizer and GSK are conducting post-marketing safety studies to monitor GBS cases among vaccine recipients.











